- Home
- TBRG vs INBX Comparison
TBRG vs INBX Comparison
Compare TBRG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- INBX
- Stock Information
- Founded
- TBRG 1979
- INBX 2010
- Country
- TBRG United States
- INBX United States
- Employees
- TBRG N/A
- INBX N/A
- Industry
- TBRG
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- TBRG
- INBX Health Care
- Exchange
- TBRG NYSE
- INBX Nasdaq
- Market Cap
- TBRG 186.6M
- INBX 232.2M
- IPO Year
- TBRG N/A
- INBX 2020
- Fundamental
- Price
- TBRG $12.35
- INBX $15.36
- Analyst Decision
- TBRG Buy
- INBX Hold
- Analyst Count
- TBRG 2
- INBX 1
- Target Price
- TBRG $13.50
- INBX N/A
- AVG Volume (30 Days)
- TBRG 57.4K
- INBX 103.6K
- Earning Date
- TBRG 11-06-2024
- INBX 08-13-2024
- Dividend Yield
- TBRG N/A
- INBX N/A
- EPS Growth
- TBRG N/A
- INBX N/A
- EPS
- TBRG N/A
- INBX 118.83
- Revenue
- TBRG $336,557,000.00
- INBX $1,687,000.00
- Revenue This Year
- TBRG $0.94
- INBX N/A
- Revenue Next Year
- TBRG $4.58
- INBX N/A
- P/E Ratio
- TBRG N/A
- INBX $0.13
- Revenue Growth
- TBRG N/A
- INBX 24.26
- 52 Week Low
- TBRG $7.55
- INBX $10.80
- 52 Week High
- TBRG $17.28
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- TBRG 48.70
- INBX 63.81
- Support Level
- TBRG $11.77
- INBX $14.51
- Resistance Level
- TBRG $12.84
- INBX $15.63
- Average True Range (ATR)
- TBRG 0.40
- INBX 0.72
- MACD
- TBRG -0.10
- INBX 0.09
- Stochastic Oscillator
- TBRG 20.54
- INBX 71.11
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.